Literature DB >> 30034594

Plasmin-Binding Tripeptide-Decorated Liposomes Loading Pyrazolo[3,4-d]pyrimidines for Targeting Hepatocellular Carcinoma.

Pierpaolo Calandro1,2, Giulia Iovenitti1, Claudio Zamperini1,3, Francesca Candita1, Elena Dreassi1, Mario Chiariello2, Adriano Angelucci4, Silvia Schenone5, Maurizio Botta1,3,6, Arianna Mancini1,7.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most fatal cancer types worldwide. HCC cells were proved to overexpress c-Src and Sgk1, a tyrosine and a serine-threonine kinase, respectively, whose role is crucial for the development and progression of the tumor. Pyrazolo[3,4-d]pyrimidine derivatives are a class of tyrosine kinase inhibitors that have shown good activity against HepG2. HCC cells were also proved to overexpress plasmin, which is localized on the cell surface bound to its receptors. In this study, a tripeptide with sequence d-Ala-Phe-Lys, which binds a specific reactive site of plasmin, was synthesized and characterized. This tripeptide was used to decorate liposomes encapsulating three selected pyrazolo[3,4-d]pyrimidines. Liposomes bearing tripeptide have been characterized, not showing remarkable differences with respect to the corresponding tripeptide-free liposomes. In vitro HepG2 cell uptake profiles and cytotoxicities showed that the presence of the tripeptide on the liposomal membrane surface improves the cell-penetrating ability of liposomes and increases the activity of two of the three tested compounds.

Entities:  

Year:  2018        PMID: 30034594      PMCID: PMC6047171          DOI: 10.1021/acsmedchemlett.8b00062

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  40 in total

1.  Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases.

Authors:  A Taguchi; D C Blood; G del Toro; A Canet; D C Lee; W Qu; N Tanji; Y Lu; E Lalla; C Fu; M A Hofmann; T Kislinger; M Ingram; A Lu; H Tanaka; O Hori; S Ogawa; D M Stern; A M Schmidt
Journal:  Nature       Date:  2000-05-18       Impact factor: 49.962

Review 2.  Cell-associated plasminogen activation: regulation and physiological functions.

Authors:  O Saksela; D B Rifkin
Journal:  Annu Rev Cell Biol       Date:  1988

3.  The role of annexin A2 in tumorigenesis and cancer progression.

Authors:  Noor A Lokman; Miranda P Ween; Martin K Oehler; Carmela Ricciardelli
Journal:  Cancer Microenviron       Date:  2011-03-05

4.  Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes.

Authors:  B Altenberg; K O Greulich
Journal:  Genomics       Date:  2004-12       Impact factor: 5.736

Review 5.  Src in cancer: deregulation and consequences for cell behaviour.

Authors:  Margaret C Frame
Journal:  Biochim Biophys Acta       Date:  2002-06-21

6.  Suppression of SRC Signaling Is Effective in Reducing Synergy between Glioblastoma and Stromal Cells.

Authors:  Alessia Calgani; Giulia Vignaroli; Claudio Zamperini; Federica Coniglio; Claudio Festuccia; Ernesto Di Cesare; Giovanni Luca Gravina; Claudia Mattei; Flora Vitale; Silvia Schenone; Maurizio Botta; Adriano Angelucci
Journal:  Mol Cancer Ther       Date:  2016-05-11       Impact factor: 6.261

Review 7.  Current trends in the use of liposomes for tumor targeting.

Authors:  Pranali P Deshpande; Swati Biswas; Vladimir P Torchilin
Journal:  Nanomedicine (Lond)       Date:  2013-09       Impact factor: 5.307

8.  Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma.

Authors:  D Cantero; H Friess; J Deflorin; A Zimmermann; M A Bründler; E Riesle; M Korc; M W Büchler
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 9.  Tumor targeting using liposomal antineoplastic drugs.

Authors:  Jörg Huwyler; Jürgen Drewe; Stephan Krähenbuhl
Journal:  Int J Nanomedicine       Date:  2008

10.  SRC family kinase (SFK) inhibition reduces rhabdomyosarcoma cell growth in vitro and in vivo and triggers p38 MAP kinase-mediated differentiation.

Authors:  Nadia Casini; Iris Maria Forte; Gianmarco Mastrogiovanni; Francesca Pentimalli; Adriano Angelucci; Claudio Festuccia; Valentina Tomei; Elisa Ceccherini; Domenico Di Marzo; Silvia Schenone; Maurizio Botta; Antonio Giordano; Paola Indovina
Journal:  Oncotarget       Date:  2015-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.